Form 4: Acumen Pharma CMO Sells Shares for Tax Obligations

Acumen Pharmaceuticals' Chief Medical Officer, Eric Siemers, sold common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals, Inc. (ABOS), reported sales of common stock.
• The sales occurred on January 21, 2026, and January 22, 2026.
• A total of 3,226 shares were sold across both transactions.
• These transactions were automatic 'sell to cover' sales to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Siemers on September 3, 2024.
• Following these transactions, Mr. Siemers beneficially owns 255,371 shares of Acumen Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine 'sell to cover' transaction by an insider to satisfy tax obligations related to RSU vesting, executed under a pre-arranged 10b5-1 plan. This is a neutral event and does not indicate a change in management's confidence or company fundamentals.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sales represent the number of shares sold by the Reporting Person through an automatic 'sell to cover' transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2024.
• The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700.

Industry Context

This insider transaction report is specific to an individual executive's equity compensation and tax obligations and does not directly relate to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: Minor, as it's a routine, pre-planned tax-related sale by an executive, not indicative of a change in company fundamentals or management's discretionary selling.

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, Eric Siemers, Chief Medical Officer, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1 Plan